News

Filter

501 to 510 of 96601 results

Compromised vials of Roche's MabThera found in Germany

Compromised vials of Roche's MabThera found in Germany

15-09-2014

Swiss drug major Roche has said that compromised vials of its arthritis and cancer drug MabThera had…

GermanyHerceptinLegalMabTheraOncologyPharmaceuticalProductionRegulationRoche

India’s Dept of Biotech plans financial help for the biotech industry

India’s Dept of Biotech plans financial help for the biotech industry

15-09-2014

Anti-cancer compounds, immunogens against H1N1, cheap recombinant human insulin, stem cell research -…

BiotechnologyFinancialIndiaResearch

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

14-09-2014

Shares of US biotech firm Amarin Corp tanked 23.7% to $1.38 on Friday in heavy trading, when the company…

AmarinCardio-vascularGlaxoSmithKlineLovazaPharmaceuticalRegulationVascepa

Lilly’s Cyramza meets endpoints in Ph III colorectal cancer trial

Lilly’s Cyramza meets endpoints in Ph III colorectal cancer trial

14-09-2014

US pharma major Eli Lilly says that the RAISE trial, a Phase III study of ramucirumab (already marketed…

CyramzaEli LillyOncologyPharmaceuticalResearch

EMA’s PRAC concludes review of Valdoxan/Thymanax

EMA’s PRAC concludes review of Valdoxan/Thymanax

14-09-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has concluded its regular…

EuropeNeurologicalPharmaceuticalRegulationServierThymanaxValdoxan

Novartis shows leadership in ophthalmology at EURETINA

Novartis shows leadership in ophthalmology at EURETINA

14-09-2014

New data on Swiss pharma major Novartis’ ophthalmic drugs Lucentis (ranibizumab) and Jetrea (ocriplasmin)…

JetreaLucentisNovartisOphthalmicsPharmaceuticalResearch

Merck Serono pulls plug on tecemotide in Stage III NSCLC

Merck Serono pulls plug on tecemotide in Stage III NSCLC

12-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, is to discontinue the clinical development…

BiotechnologyGermanyMerck SeronoOncologyResearch

501 to 510 of 96601 results

Back to top